Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trialOriginal Article Published on 2023-02-052024-09-04 Journal: Chinese medical journal [Category] 대상포진, [키워드] dose reduction rheumatoid arthritis Tofacitinib Withdrawal [DOI] 10.1097/CM9.0000000000002561 PMC 바로가기 [Article Type] Original Article
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibClinical Trial Published on 2023-01-052023-05-31 Journal: Inflammatory bowel diseases [Category] 두창, 수두, 홍역, [키워드] herpes zoster Tofacitinib ulcerative colitis [DOI] 10.1093/ibd/izac063 PMC 바로가기 [Article Type] Clinical Trial
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical ProgramArticle Published on 2023-01-052023-05-31 Journal: Inflammatory bowel diseases [Category] 두창, 수두, 홍역, [키워드] age clinical response Safety Tofacitinib ulcerative colitis [DOI] 10.1093/ibd/izac084 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic PharmacokineticsOriginal Research Published on 2022-10-062024-09-04 Journal: Cellular and molecular gastroenterology and hepato [Category] 대상포진, [키워드] 3D, 3-Dimensional ASV, Amplicon sequence variant ATP, adenosine triphosphate CD, Crohn’s disease CFSE, carboxyfluorescein succinimidyl ester DI, division index DSS, dextran sulfate sodium ELISA, enzyme-linked immunosorbent assay ENT, equilibrative nucleoside transporter FSC, forward scatter IBD, Inflammatory bowel disease IEC, intestinal epithelial cell IFNγ, interferon γ IHC, immunohistochemistry IL, interleukin Inflammatory bowel disease JAK inhibitor JAK, Janus kinase JAKi, Janus kinase inhibitor LC-MS/MS, liquid chromatography–tandem mass spectrometry LPS, lipopolysaccharide M-CSF, macrophage colony-stimulating factor mRNA, messenger RNA Mucosal inflammation PBMC, peripheral blood mononuclear cell PBS, phosphate-buffered saline PHA, phytohemagglutinin pharmacokinetics PI, proliferation index STAT, signal transducers and activator of transcription Th, T helper TNF-α, tumor necrosis factor α Tofacitinib UC, ulcerative colitis [DOI] 10.1016/j.jcmgh.2021.09.004 PMC 바로가기 [Article Type] Original Research
Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta‐analysisReviews Published on 2022-10-022024-09-04 Journal: International journal of rheumatic diseases [Category] 대상포진, [키워드] dactylitis Enthesitis filgotinib Janus kinase inhibitors psoriasis psoriatic arthritis Tofacitinib Upadacitinib [DOI] 10.1111/1756-185X.14447 PMC 바로가기 [Article Type] Reviews
Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods studyArticle Published on 2022-10-012022-11-15 Journal: Health technology assessment (Winchester, England) [Category] 진단, [키워드] administration assessment carried Characteristics Consensus COVID-19 pandemic drug duration of symptom Effectiveness evaluate experiment experiments Factor Future greater Health personnel health-care highlight IMPROVE Inflammatory bowel disease influence information journal lack less library Necrosis NHS NIHR offered over Patient Patient preference patients per day predicted Prednisolone preference preferences Probability professional professionals qualitative research randomised controlled trial Randomised controlled trials recommendation Research respond risk sample sizes secondary care Selection bias severity Side effect Side effects subject surveys and questionnaires Symptoms technology therapeutic benefits Tofacitinib Treatment ulcerative ulcerative colitis undergo website [DOI] 10.3310/RHXR5192 PMC 바로가기
Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western Indiaarticle Published on 2022-10-012024-09-02 Journal: Clinical Rheumatology [Category] 대상포진, [키워드] Generic registry rheumatoid arthritis South Asia Tofacitinib [DOI] 10.1007/s10067-022-06205-z PMC 바로가기 [Article Type] article
Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysisarticle Published on 2022-09-272024-09-02 Journal: BMC Rheumatology [Category] 대상포진, [키워드] jak inhibitors psoriasis psoriatic arthritis Tofacitinib Upadacitinib [DOI] 10.1186/s41927-022-00287-7 PMC 바로가기 [Article Type] article
Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection Research Published on 2022-05-122022-10-05 Journal: Scientific Reports [Category] 신약개발, 치료제, [키워드] approach approved Baricitinib can be used drug-target Effect elevated Evidence explain HCV highlight hypomagnesemia identification identify in vitro assays in vitro study include increased risk Interaction JAK inhibitor jak inhibitors Ligand machine learning approach mechanism modulation PDE10A pharmacological PKN2 Potential predict required risk similarity target thrombosis Tofacitinib TRPM6 Vascular viral infection while [DOI] 10.1038/s41598-022-11879-1 [Article Type] Research